ANIK up +1.76% percent Today $ANIK High is at 41.8
Post# of 30
Posted On: 11/11/2014 2:48:29 PM
ANIK up +1.76% percent Today $ANIK High is at 41.88 and the Low 41.31 with current volume of 89,307.
Recent News posted below.
Anika Therapeutics Inc ANIK other info.
http://investorshangout.com/Anika-Therapeutic...NIK-53336/
ANIK Anika Therapeutics Inc Recent Headline News
Update: Anika Therapeutics Q3 2014 Earnings
Andy Batts - at Seeking Alpha - 26 mins ago
ANIK: 41.46 (+0.55)
Global Anti-Adhesion Products Industry
PR Newswire - Tue Nov 11, 10:23AM CST
This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
ANIK: 41.46 (+0.55)
Center for Medicare & Medicaid Services Announces That a Unique Reimbursement Code is Assigned to Anika's MONOVISC(R) Product
Business Wire - Mon Nov 10, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Center for Medicare & Medicaid Services ("CMS"
has assigned a unique Healthcare Common Procedure Coding System ("HCPCS" code, or J-Code, to its product MONOVISC(R). The issuance of this code by CMS sets national Medicare reimbursement rates for the product. The new J-Code becomes effective on January 1, 2015.
ANIK: 41.46 (+0.55)
Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 5:25AM CST
ANIK: 41.46 (+0.55)
Anika ups revenues 24% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:10PM CDT
ANIK: 41.46 (+0.55)
Anika Therapeutics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:11PM CDT
ANIK: 41.46 (+0.55)
Anika Therapeutics Reports Third-Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 3:05PM CDT
--Earnings per Share Increase to $0.40 from $0.33
ANIK: 41.46 (+0.55)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:35PM CDT
CSGP: 160.02 (+0.04), CNW: 46.03 (-0.32), ACMP: 62.11 (-0.53), BGC: 13.98 (-0.07), DAC: 6.24 (-0.04), AIZ: 67.70 (-0.30), AEM: 24.26 (+1.25), ESRT: 15.95 (-0.07), CAR: 57.31 (-0.66), CWT: 25.35 (-0.28), AHL: 43.28 (-0.27), CLUB: 6.10 (-0.67), CAVM: 52.50 (-0.10), CJES: 18.83 (-0.09), FB: 74.26 (-0.74), AKAM: 60.89 (-0.18), EXR: 58.52 (-0.13), DWA: 21.91 (-0.18), EXL: 12.93 (-0.09), ANIK: 41.46 (+0.55), CLD: 13.07 (+0.04), ALL: 66.62 (-0.14), DRIV: 24.52 (-0.25), EQIX: 222.40 (+4.37), ESV: 39.45 (-0.47), ASGN: 30.00 (-0.02), AUY: 3.93 (+0.27), ACHC: 61.11 (-0.18), CALX: 11.32 (-0.06), CSII: 29.98 (-0.04), AFOP: 13.70 (unch), ARAY: 7.10 (+0.20), AEGN: 19.50 (-0.32), ATML: 7.57 (-0.03), CENX: 27.46 (+0.14), CUZ: 12.83 (-0.17), CACI: 85.30 (+1.38), ACGL: 57.19 (-0.07), AXS: 49.18 (-0.04), BMR: 21.58 (-0.07), ARII: 68.16 (-0.92), CBG: 32.47 (+0.66), CW: 70.59 (+0.03), DRE: 19.68 (+0.09), ABX: 11.79 (+0.44), CBL: 18.98 (-0.42), CHDN: 104.26 (-0.17), CMO: 12.62 (-0.04), CATM: 38.16 (+0.24), BLKB: 44.27 (-0.48), BIDU: 247.58 (unch), EQY: 24.16 (+0.01), ARRS: 28.63 (-1.83), ALDW: 18.69 (-0.55), CRUS: 19.56 (-0.13), CEMP: 14.27 (+0.47), CRL: 64.03 (+0.10)
Anika Therapeutics reports on October 29
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 3:57PM CDT
ANIK: 41.46 (+0.55)
Anika Therapeutics Announces Date of Third-Quarter 2014 Financial Results Conference Call
Business Wire - Thu Oct 16, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its third-quarter 2014 financial results after the close of the market on Wednesday, October 29, 2014. The company plans to hold a conference call the next day, Thursday, October 30 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
ANIK: 41.46 (+0.55)
Global Regenerative Medicine (Bone and Joint) Market Forecasts and Opportunities, 2019
M2 - Wed Oct 08, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5879mp/regenerative) has announced the addition of the "Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019 U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital defects, disease and age. Moreover, it has included stem cell therapy, tissue engineering and biomaterial under the umbrella of regenerative medicine. Regenerative medicine has wide areas of application such as cardiovascular, neurology, orthopedic and musculoskeletal diseases and disorders. The global market for regenerative medicine bone and joint application is dominated by various bone graft substitute in 2012. However, it is expected that tissue engineering will become a lucrative market in future. Factors such as growing geriatric population, favorable government support and increasing bone and joint reconstructive surgeries accentuate growth of the global regenerative medicine bone and joint application market. Scope of the Report The global regenerative medicine (bone and joint) market is segmented as follows: - Regenerative Medicine (Bone and Joint) Market, by Technology - Stem Cell Therapy - Biomaterial - Tissue Engineering Regenerative Medicine (Bone and Joint) Market, by Application - Bone Graft Substitutes - Osteoarticular Diseases - Allogeneic Bones - Autogenic Bones - Others Major market players profiled in this report includes: - Anika Therapeutics, Inc - Arthrex, Inc - Baxter International, Inc. - CONMED Corporation - DePuy Synthes, Inc. - Medtronic, Inc. - Smith & Nephew PLC - Stryker Corporation - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/58...generative
ZMH: 110.95 (+0.53), SNN: 33.87 (+0.41), MDT: 68.82 (+0.11), BAX: 70.50 (-0.13), CNMD: 42.29 (+0.20), ANIK: 41.46 (+0.55), SYK: 88.53 (+0.09)
11.5% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Sep 29, 11:21AM CDT
SmarTrend identified a Downtrend for Anika Therapeutics (NASDAQ:ANIK) on August 1st, 2014 at $40.68. In approximately 2 months, Anika Therapeutics has returned 11.53% as of today's recent price of $35.99.
ANIK: 41.46 (+0.55)
Global Anti-Adhesion Products - Strategic Business Report 2014
M2 - Mon Aug 18, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9msqpk/antiadhesion) has announced the addition of the "Anti-Adhesion Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as: - Anika Therapeutics, Inc. - Baxter Healthcare Ltd. - Covidien - Ethicon, Inc. - FzioMed, Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Study Reliability and Reporting Limitations - Disclaimers - Data Interpretation & Reporting Level - Quantitative Techniques & Analytics - Product Definitions and Scope of Study - Adhesion - Anti-Adhesion Products - General/Abdominal Surgery - Pelvic/Gynecological Surgery - Other Surgical Procedures II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. ADVANCED WOUND CARE TECHNOLOGIES AN OVERVIEW OF THE LARGER MARKET 3. PRODUCT OVERVIEW 4. PRODUCT INNOVATIONS/APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 19 (including Divisions/Subsidiaries 22) - The United States (9) - Japan (1) - Europe (11) - Germany (2) - The United Kingdom (3) - Rest of Europe (6) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/9m...tiadhesion
ANIK: 41.46 (+0.55)
Regenerative Medicine Market 2014-2020 - Global Strategic Business Report
M2 - Thu Aug 14, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwcn7x/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. The report profiles 46 companies including many key and niche players such as: - AlloSource - Anika Therapeutics, Inc. - Biomet, Inc. - Bioventus LLC - DePuy Synthes Companies Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Regenerative Medicine A Macro Perspective 3. Bone And Joint Regenerative Medicine An Overview 4. Competitive Landscape 5. Regenerative Medicine In Other Areas 6. Regulatory Environment 7. A Peek Into The Global Orthopedic Industry 8. Research And Development 9. Product Overview 10. Product Innovations/Introductions 11. Recent Industry Activity 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Asia-Pacific 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 46 (including Divisions/Subsidiaries 51) - The United States (38) - Europe (11) - Germany (2) - The United Kingdom (2) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/jw...generative
ANIK: 41.46 (+0.55)
Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis to 2019 for the $6.4 Billion Industry
M2 - Mon Aug 11, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sb3q8w/regenerative) has announced the addition of the "Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019. The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. Moreover, tissue engineering is expected to grow at the highest CAGR during the forecast period. In addition, the global market for regenerative medicine (bone and joint) is segmented based on application as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. Autogenic bone application segment is expected to grow at the highest CAGR during the forecast period 2013 to 2019. The global regenerative medicine (bone and joint) market is segmented as follows: - Regenerative Medicine (Bone and Joint) Market, by Technology - Stem Cell Therapy - Biomaterial - Tissue Engineering Regenerative Medicine (Bone and Joint) Market, by Application - Bone Graft Substitutes - Osteoarticular Diseases - Allogeneic Bones - Autogenic Bones - Others Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Regenerative Medicine (Bone and Joint) Market, by Technology Chapter 5 Regenerative Medicine (Bone and Joint) Market, by Applications Chapter 6 Regenerative Medicine (Bone and Joint) Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Anika Therapeutics, Inc. - Arthrex, Inc. - Baxter International, Inc. - CONMED Corporation - DePuy Synthes, Inc. - Medtronic, Inc. - Smith & Nephew plc - Stryker Corporation - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sb...generative
ZMH: 110.95 (+0.53), SNN: 33.87 (+0.41), MDT: 68.81 (+0.10), BAX: 70.49 (-0.14), CNMD: 42.29 (+0.20), ANIK: 41.46 (+0.55), SYK: 88.53 (+0.09)
Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
Business Wire - Mon Aug 04, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 10:30 a.m. ET. The conference is being held at the InterContinental Hotel in Boston, Massachusetts.
ANIK: 41.46 (+0.55)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 19.00 (unch), BGFV: 12.97 (+0.04), WATT: 9.50 (-0.19), MGAM: 35.39 (+0.20), DEST: 14.91 (-0.37), EDGW: 7.15 (+0.13), MINI: 44.25 (+0.71), ANIK: 41.46 (+0.55), GLUU: 3.80 (+0.01), BWLD: 161.72 (+2.49), MMSI: 15.30 (+0.11), FEIC: 83.86 (-0.15)
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
at Investor's Business Daily - Thu Jul 31, 10:50AM CDT
Stocks lost more ground near the midpoint of Thursday's session. They had been under pressure from the start amid Argentina's debt default and mixed economic data. The Nasdaq slumped 1.6%, hurt by software and chip stocks. The S&P 500 dropped 1.3%,...
KNDI: 15.61 (+0.75), KS: 31.07 (-0.41), YELP: 60.98 (+1.91), ANIK: 41.46 (+0.55)
Anika Therapeutics partners with Medline for marketing of wound care product Hyalomatrix
M2 - Thu Jul 31, 6:15AM CDT
Therapeutic products company Anika Therapeutics (NasdaqGS:ANIK) reported on Wednesday the execution of an exclusive agreement to commercialise its Hyalomatrix in the US in partnership with Medline Industries
ANIK: 41.46 (+0.55)
Recent News posted below.
Anika Therapeutics Inc ANIK other info.
http://investorshangout.com/Anika-Therapeutic...NIK-53336/
ANIK Anika Therapeutics Inc Recent Headline News
Update: Anika Therapeutics Q3 2014 Earnings
Andy Batts - at Seeking Alpha - 26 mins ago
ANIK: 41.46 (+0.55)
Global Anti-Adhesion Products Industry
PR Newswire - Tue Nov 11, 10:23AM CST
This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
ANIK: 41.46 (+0.55)
Center for Medicare & Medicaid Services Announces That a Unique Reimbursement Code is Assigned to Anika's MONOVISC(R) Product
Business Wire - Mon Nov 10, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Center for Medicare & Medicaid Services ("CMS"
has assigned a unique Healthcare Common Procedure Coding System ("HCPCS" code, or J-Code, to its product MONOVISC(R). The issuance of this code by CMS sets national Medicare reimbursement rates for the product. The new J-Code becomes effective on January 1, 2015. ANIK: 41.46 (+0.55)
Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 5:25AM CST
ANIK: 41.46 (+0.55)
Anika ups revenues 24% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:10PM CDT
ANIK: 41.46 (+0.55)
Anika Therapeutics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:11PM CDT
ANIK: 41.46 (+0.55)
Anika Therapeutics Reports Third-Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 3:05PM CDT
--Earnings per Share Increase to $0.40 from $0.33
ANIK: 41.46 (+0.55)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:35PM CDT
CSGP: 160.02 (+0.04), CNW: 46.03 (-0.32), ACMP: 62.11 (-0.53), BGC: 13.98 (-0.07), DAC: 6.24 (-0.04), AIZ: 67.70 (-0.30), AEM: 24.26 (+1.25), ESRT: 15.95 (-0.07), CAR: 57.31 (-0.66), CWT: 25.35 (-0.28), AHL: 43.28 (-0.27), CLUB: 6.10 (-0.67), CAVM: 52.50 (-0.10), CJES: 18.83 (-0.09), FB: 74.26 (-0.74), AKAM: 60.89 (-0.18), EXR: 58.52 (-0.13), DWA: 21.91 (-0.18), EXL: 12.93 (-0.09), ANIK: 41.46 (+0.55), CLD: 13.07 (+0.04), ALL: 66.62 (-0.14), DRIV: 24.52 (-0.25), EQIX: 222.40 (+4.37), ESV: 39.45 (-0.47), ASGN: 30.00 (-0.02), AUY: 3.93 (+0.27), ACHC: 61.11 (-0.18), CALX: 11.32 (-0.06), CSII: 29.98 (-0.04), AFOP: 13.70 (unch), ARAY: 7.10 (+0.20), AEGN: 19.50 (-0.32), ATML: 7.57 (-0.03), CENX: 27.46 (+0.14), CUZ: 12.83 (-0.17), CACI: 85.30 (+1.38), ACGL: 57.19 (-0.07), AXS: 49.18 (-0.04), BMR: 21.58 (-0.07), ARII: 68.16 (-0.92), CBG: 32.47 (+0.66), CW: 70.59 (+0.03), DRE: 19.68 (+0.09), ABX: 11.79 (+0.44), CBL: 18.98 (-0.42), CHDN: 104.26 (-0.17), CMO: 12.62 (-0.04), CATM: 38.16 (+0.24), BLKB: 44.27 (-0.48), BIDU: 247.58 (unch), EQY: 24.16 (+0.01), ARRS: 28.63 (-1.83), ALDW: 18.69 (-0.55), CRUS: 19.56 (-0.13), CEMP: 14.27 (+0.47), CRL: 64.03 (+0.10)
Anika Therapeutics reports on October 29
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 3:57PM CDT
ANIK: 41.46 (+0.55)
Anika Therapeutics Announces Date of Third-Quarter 2014 Financial Results Conference Call
Business Wire - Thu Oct 16, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its third-quarter 2014 financial results after the close of the market on Wednesday, October 29, 2014. The company plans to hold a conference call the next day, Thursday, October 30 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
ANIK: 41.46 (+0.55)
Global Regenerative Medicine (Bone and Joint) Market Forecasts and Opportunities, 2019
M2 - Wed Oct 08, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5879mp/regenerative) has announced the addition of the "Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019 U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital defects, disease and age. Moreover, it has included stem cell therapy, tissue engineering and biomaterial under the umbrella of regenerative medicine. Regenerative medicine has wide areas of application such as cardiovascular, neurology, orthopedic and musculoskeletal diseases and disorders. The global market for regenerative medicine bone and joint application is dominated by various bone graft substitute in 2012. However, it is expected that tissue engineering will become a lucrative market in future. Factors such as growing geriatric population, favorable government support and increasing bone and joint reconstructive surgeries accentuate growth of the global regenerative medicine bone and joint application market. Scope of the Report The global regenerative medicine (bone and joint) market is segmented as follows: - Regenerative Medicine (Bone and Joint) Market, by Technology - Stem Cell Therapy - Biomaterial - Tissue Engineering Regenerative Medicine (Bone and Joint) Market, by Application - Bone Graft Substitutes - Osteoarticular Diseases - Allogeneic Bones - Autogenic Bones - Others Major market players profiled in this report includes: - Anika Therapeutics, Inc - Arthrex, Inc - Baxter International, Inc. - CONMED Corporation - DePuy Synthes, Inc. - Medtronic, Inc. - Smith & Nephew PLC - Stryker Corporation - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/58...generative
ZMH: 110.95 (+0.53), SNN: 33.87 (+0.41), MDT: 68.82 (+0.11), BAX: 70.50 (-0.13), CNMD: 42.29 (+0.20), ANIK: 41.46 (+0.55), SYK: 88.53 (+0.09)
11.5% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Sep 29, 11:21AM CDT
SmarTrend identified a Downtrend for Anika Therapeutics (NASDAQ:ANIK) on August 1st, 2014 at $40.68. In approximately 2 months, Anika Therapeutics has returned 11.53% as of today's recent price of $35.99.
ANIK: 41.46 (+0.55)
Global Anti-Adhesion Products - Strategic Business Report 2014
M2 - Mon Aug 18, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9msqpk/antiadhesion) has announced the addition of the "Anti-Adhesion Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as: - Anika Therapeutics, Inc. - Baxter Healthcare Ltd. - Covidien - Ethicon, Inc. - FzioMed, Inc. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Study Reliability and Reporting Limitations - Disclaimers - Data Interpretation & Reporting Level - Quantitative Techniques & Analytics - Product Definitions and Scope of Study - Adhesion - Anti-Adhesion Products - General/Abdominal Surgery - Pelvic/Gynecological Surgery - Other Surgical Procedures II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. ADVANCED WOUND CARE TECHNOLOGIES AN OVERVIEW OF THE LARGER MARKET 3. PRODUCT OVERVIEW 4. PRODUCT INNOVATIONS/APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 19 (including Divisions/Subsidiaries 22) - The United States (9) - Japan (1) - Europe (11) - Germany (2) - The United Kingdom (3) - Rest of Europe (6) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/9m...tiadhesion
ANIK: 41.46 (+0.55)
Regenerative Medicine Market 2014-2020 - Global Strategic Business Report
M2 - Thu Aug 14, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jwcn7x/regenerative) has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Regenerative Medicine in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. The report profiles 46 companies including many key and niche players such as: - AlloSource - Anika Therapeutics, Inc. - Biomet, Inc. - Bioventus LLC - DePuy Synthes Companies Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Regenerative Medicine A Macro Perspective 3. Bone And Joint Regenerative Medicine An Overview 4. Competitive Landscape 5. Regenerative Medicine In Other Areas 6. Regulatory Environment 7. A Peek Into The Global Orthopedic Industry 8. Research And Development 9. Product Overview 10. Product Innovations/Introductions 11. Recent Industry Activity 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Asia-Pacific 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 46 (including Divisions/Subsidiaries 51) - The United States (38) - Europe (11) - Germany (2) - The United Kingdom (2) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Africa (1) For more information visit http://www.researchandmarkets.com/research/jw...generative
ANIK: 41.46 (+0.55)
Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis to 2019 for the $6.4 Billion Industry
M2 - Mon Aug 11, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sb3q8w/regenerative) has announced the addition of the "Regenerative Medicine Market (Bone and Joint) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019. The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. Moreover, tissue engineering is expected to grow at the highest CAGR during the forecast period. In addition, the global market for regenerative medicine (bone and joint) is segmented based on application as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. Autogenic bone application segment is expected to grow at the highest CAGR during the forecast period 2013 to 2019. The global regenerative medicine (bone and joint) market is segmented as follows: - Regenerative Medicine (Bone and Joint) Market, by Technology - Stem Cell Therapy - Biomaterial - Tissue Engineering Regenerative Medicine (Bone and Joint) Market, by Application - Bone Graft Substitutes - Osteoarticular Diseases - Allogeneic Bones - Autogenic Bones - Others Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Regenerative Medicine (Bone and Joint) Market, by Technology Chapter 5 Regenerative Medicine (Bone and Joint) Market, by Applications Chapter 6 Regenerative Medicine (Bone and Joint) Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Anika Therapeutics, Inc. - Arthrex, Inc. - Baxter International, Inc. - CONMED Corporation - DePuy Synthes, Inc. - Medtronic, Inc. - Smith & Nephew plc - Stryker Corporation - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sb...generative
ZMH: 110.95 (+0.53), SNN: 33.87 (+0.41), MDT: 68.81 (+0.10), BAX: 70.49 (-0.14), CNMD: 42.29 (+0.20), ANIK: 41.46 (+0.55), SYK: 88.53 (+0.09)
Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
Business Wire - Mon Aug 04, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 10:30 a.m. ET. The conference is being held at the InterContinental Hotel in Boston, Massachusetts.
ANIK: 41.46 (+0.55)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 19.00 (unch), BGFV: 12.97 (+0.04), WATT: 9.50 (-0.19), MGAM: 35.39 (+0.20), DEST: 14.91 (-0.37), EDGW: 7.15 (+0.13), MINI: 44.25 (+0.71), ANIK: 41.46 (+0.55), GLUU: 3.80 (+0.01), BWLD: 161.72 (+2.49), MMSI: 15.30 (+0.11), FEIC: 83.86 (-0.15)
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
at Investor's Business Daily - Thu Jul 31, 10:50AM CDT
Stocks lost more ground near the midpoint of Thursday's session. They had been under pressure from the start amid Argentina's debt default and mixed economic data. The Nasdaq slumped 1.6%, hurt by software and chip stocks. The S&P 500 dropped 1.3%,...
KNDI: 15.61 (+0.75), KS: 31.07 (-0.41), YELP: 60.98 (+1.91), ANIK: 41.46 (+0.55)
Anika Therapeutics partners with Medline for marketing of wound care product Hyalomatrix
M2 - Thu Jul 31, 6:15AM CDT
Therapeutic products company Anika Therapeutics (NasdaqGS:ANIK) reported on Wednesday the execution of an exclusive agreement to commercialise its Hyalomatrix in the US in partnership with Medline Industries
ANIK: 41.46 (+0.55)
(0)
(0)Anika Therapeutics Inc. (ANIK) Stock Research Links
Scroll down for more posts ▼